| |
| Karolinska Development
AB (publ)
org. nr. 556707-5048
Registered office: Solna
© Karolinska Development 2008 |
|
|
Karolinska Development
Karolinska
Development uses a unique commercialization model to capture the
hidden value in academic research, and to exploit its unrealized
potential for the betterment of human health through commercial
development.
Today our portfolio consists of around 40 start-up companies and
after only four years, four companies, (Dilafor, Calabar, Oncopeptides,
Umecrine Mood) have entered phase II studies, and three companies,
(Avaris, Independent Pharmaceuticals, Spectracure) have initiated
phase I studies. One company, Cogmed, has launched an IT-based product
in the market to treat ADHD. A second company, (Athera Biotechnologies),
has also launched a product, CVDefine™, a test used to aid
risk assesment for the development of cardiovascular disease.
 |
 |
 |
| Calabar AB develops innovative therapies for treating
dry mouth.
Read
more...
|
|
Athera Biotechnologies AB develops products for risk assessment
and prevention of cardiovascular events related to inflammatory
and immunological mechanisms.
Read
more...
|


|
|

|
|